Effects of chronic dobutamine administration on hearts of normal and hypertensive rats.
We have previously shown that physical conditioning in the rat improves cardiac mechanics and biochemistry and normalizes the cardiac contractile protein abnormalities associated with renovascular hypertension. Since chronic adrenergic stimulation with dobutamine simulates some aspects of physical conditioning, this study was undertaken to investigate the effects of chronic dobutamine administration on normal and hypertensive rat hearts. Four groups of female animals were studied: controls, dobutamine-treated (2 mg/kg twice daily), renovascular hypertensives, and dobutamine-treated hypertensives. Animals were killed after 8-10 weeks and cardiac histology, myosin biochemistry, and mechanics in an isolated heart perfusion apparatus were studied. Dobutamine, unlike hypertension, was not associated with histological evidence of myocardial damage but did increase cardiac mass by 10% and calcium-activated myosin ATPase activity by 13%. Hypertension was associated with a 24% increase in mass, a 24% decrease in ATPase activity, and a shift in the myosin isoenzyme pattern from V1 to V3. The combined stimuli caused additive hypertrophy (44%) and normalized myosin biochemistry and isomyosin distribution. Dobutamine treatment was not associated with significant improvements in pump or muscle function in control or hypertensive hearts. Thus chronic dobutamine treatment, like physical conditioning, induces a physiological cardiac hypertrophy in rats that is associated with improved myosin enzymology and normalization of the contractile protein abnormalities associated with hypertension. Unlike physical conditioning, however, these biochemical alterations do not result in improved contractile function as measured in an isolated buffer-perfused heart apparatus.
Buttrick
P
P
Department of Medicine, Montefiore Medical Center, Bronx, New York 10467.
Malhotra
A
A
Factor
S
S
Geenen
D
D
Scheuer
J
J
D000251:Adenosine Triphosphatases / Q000378:metabolism; D000818:Animals; D001835:Body Weight; D006332:Cardiomegaly / Q000473:pathology; D003285:Contractile Proteins / Q000032:analysis; D004280:Dobutamine / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006321:Heart / Q000187:drug effects*; D006978:Hypertension, Renovascular / Q000188:drug therapy; D007279:Injections, Subcutaneous; D009200:Myocardial Contraction; D051381:Rats; D011919:Rats, Inbred Strains; D013963:Thyroid Hormones / Q000032:analysis; D013997:Time Factors
D003285:Contractile Proteins; D013963:Thyroid Hormones; D004280:Dobutamine; D000251:Adenosine Triphosphatases